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Considerable research efforts have recently been dedicated to the establishment of various drug delivery 
systems (DDS) that are mechanical/physical, chemical and biological/molecular DDS. In this paper, we 
report on the recent advances in site-specific drug delivery (site-specific, controlled, targeted or smart 
drug delivery are terms used interchangeably in the literature, to mean to transport a drug or a therapeutic 
agent to a desired location within the body and release it as desired with negligibly small toxicity and side 
effect compared to classical drug administration means such as peroral, parenteral, transmucosal, topical 
and inhalation) based on mechanical/physical systems consisting of implantable and robotic drug 
delivery systems. While we specifically focus on the robotic or autonomous DDS, which can be 
reprogrammable and provide multiple doses of a drug at a required time and rate, we briefly cover the 
implanted DDS, which are well-developed relative to the robotic DDS, to highlight the design and 
performance requirements, and investigate issues associated with the robotic DDS. Critical research 
issues associated with both DDSs are presented to describe the research challenges ahead of us in order 
to establish soft robotic devices for clinical and biomedical applications. 
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Considerable research efforts have recently been dedicated to the establishment of various 
drug delivery systems (DDS) which are mechanical / physical, chemical and 
biological/molecular DDS. In this paper, we report on recent advances in site-specific drug 
delivery
1
 based on mechanical / physical systems consisting of implantable and robotic drug 
delivery systems. While we specifically focus on the robotic or autonomous DDS, which can 
be reprogrammable and provide multiple doses of a drug at a required time and rate, we 
briefly cover the implanted DDS, which are well-developed relative to the robotic DDS, to 
highlight the design and performance requirements, and investigate issues associated with the 
robotic DDS. Critical research issues associated with both DDSs are presented to describe the 
research challenges ahead of us in order to establish really soft robotic devices for clinical 
and biomedical applications. 
 
Keywords: soft robotics, site-specific drug delivery, robotic drug delivery systems, capsule 
endoscope, magnetic drug carriers, gastrointestinal tract, robotic capsules 
 
1. Introduction 
In parallel to recent developments in soft smart materials and additive manufacturing (aka 3D 
printing), the field of soft robotics has recently been gathering significant momentum to bring 
a new dimension to the establishment of new robotic concepts leading to the design and 
manufacture of soft robots which will safely interact with (or operate within) the natural 
world better than their predecessors. As a sub-class of biologically inspired engineering, it is 
a new paradigm to establish innovative robotic systems made of soft materials, components, 
and active monolithic structures [1-4]. The progress in soft robotics will have a significant 
impact on medical applications including prosthetic devices, assistive devices, and 
rehabilitation devices which require human-machine interaction. The new generation of 
robots must have adaptive elasticity and the ability to interact with humans and to operate 
within the human body and they must be sufficiently miniaturised. For applications in 
medicine, they must have compliance matching with human tissues and organs, and 
                                                             
1 Site-specific, controlled, targeted or smart drug delivery are terms used interchangeably in the literature, to 
mean to transport a drug or a therapeutic agent to a desired location within the body and release it as desired 
with negligibly small toxicity and side effect compared to classical drug administration means such as peroral, 
parenteral, transmucosal, topical, and inhalation. 
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biocompatibility. Pipe inspection is another important area which will benefit from the 
progress in soft robotics. Prosthetic limbs or wearable robots are other areas which will 
significantly benefit from the developments in soft robotics. The progress in soft robotics will 
a have significant effect on other fields such as stretchable electronics, microfluidic systems 
(lab on chip systems) and in-body drug delivery systems. 
 
Site-specific drug delivery systems consist of mechanical/physical, chemical and 
biological/molecular delivery systems, as shown in Figure 1. In this paper, we focus on the 
mechanical/physical delivery systems, especially  robotic or autonomous drug delivery 
systems. We exclude (i) classical drug delivery, which refers to the development of drugs and 
nano-medicine formulations based on nano-materials and how they can be implemented in 
real day-to-day clinical practice, (ii) functional polymers, which store a drug,  and are 
responsive to internal and external stimuli in order to release the drug, and diffusion-
controlled hydrogels and other hydrophilic systems and iii) biodegradable and biocompatible 
bioactive molecules such as food proteins (e.g., casein) and the like, which are used to 
encapsulate various drugs so that their release can be controlled [5]. This review is limited to 
untethered robotic devices, excluding, for example, a flexible cable colonoscopy and its 
robotic versions with automated locomotion, where a computer controls the movement of a 
colonoscopy. A robotic colonoscopy that carries a light source, a camera, biopsy channel, and 
air/water tubing can move from the anus to the cecum with no damage to surrounding tissue 
[6]. Robotic DDS carry a drug or drugs or direct a swarm of a drug or drugs or drug 
containers to a specific location within the body where they can be released at relevant sites 
so that they can have optimal efficacy with no side effects [7].   
 
 
Figure 1: Classification of site-specific drug delivery systems. 
 
By site-specific drug delivery we mean physically carrying or transporting a drug to a 
specific location in or out of body, and discharging  or releasing  it at an appropriate (optimal) 
dose and rate at the appropriate time with negligibly small toxicity compared to the classical 
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drug administration routes. It must be noted that the drug release is a part of the drug delivery 
once the drug is at the relevant site. There is a growing need to establish such drug delivery 
systems. Classical medications such as orally taken drugs require much higher doses to obtain 
the necessary effect with a cost of systemic side-effects, especially when treating a serious 
disease such as cancer. Advantages of site-specific drug delivery are (i) a reduced dose of a 
drug, (ii) increased and stabilized drug concentration at the targeted tissue, (iii) minimized 
trauma, inflammation and side-effects, and (iv) releasing a drug according to a patient’s need 
while providing  continuous therapy. The concept of site-specific drug delivery will help to 
effectively  attain precision or personalized medicine.  
 
While the implantable DDS are internally and externally placed around the treatment area 
thorough a minimally invasive surgical operation, the robotic DDS use  a mobile system 
carrying the drug to various locations within the body to release them as programmed. The 
implantable DDS [8-11] can be in the form of biodegradable drug implants such as a polymer 
matrix filled with a drug which cannot be refilled and the drug release is not quite 
controllable as the drug diffuses out of the reservoir. It must be noted that depending on the 
polymer used, a polymer-based DDS can release the drug following a specific controlled 
release profile over a predetermined period of time, but not in real time as desired with a 
variable dose or timing. These DDS are known as encapsulated drug delivery systems. On the 
other hand, microchip-based DDS and micropump-based DDS release a drug in a controlled 
manner in real time.  
 
Robotic DDS can carry encapsulated drug containers and other formulations to the desired 
location for effective drug release but one problem associated with the robotic DDS is being 
able to anchor them before releasing the  drug and making sure that their location is 
accurately controlled so that they release the drug at the desired location [12-15]. In this 
regard, the implantable drug delivery systems are less problematic and more reliable than the 
robotic drug delivery systems for site-specific drug delivery but they have to be removed 
from the body once they complete their mission if they contain non-biodegradable 
components, or they must be left at the implantation location in order to have them disposed 
of naturally if they are made of biodegradable components. Further, specific ligands such as 
polysaccharides [69, 70] can be used for anchoring the drugs at specific locations providing 
specificity (active targeting) and more precision once the drug is delivered to a specific site.  
Usually, active implantable drug delivery systems require an on-board power source and a 
wireless communication module. This  imposes limits on the drug implantation and delivery 
period.  Unless they are externally implanted and are the only choice, active implantable 
DDS, and implantable DDS made of non-biodegradable components are  generally  to be 
preferred. 
 
We believe that the topic of site-specific drug delivery requires a multi-disciplinary approach. 
To this aim, collaboration among researchers in various disciplines such as engineering, and 
physical, chemical, biological, mathematical, and biomedical sciences would be useful in 
order to solve the fundamental and applied research problems of  establishing innovative, 
low-cost and effective DDS, drug design including drug design parameters such as the rate 
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and dose of the  drug to be delivered to relevant areas, and the way a drug will be released in 
order to attain optimal efficacy with  enhanced permeability and retention. An integrated 
approach needs to be followed in order to shorten the path between the research outcomes in 
the laboratory environment and their translation into day-to-day clinical practice in order to 
make a significant impact on medical treatment, resulting in  improved health care for the 
community. 
 
2. Implantable Drug Delivery Systems 
The implantable DDS consist of microchip-based, encapsulated and micropump-based DDS. 
Microchip-based DDS, also called ‘pharmacy-on-a-chip’ [9, 16], which are fabricated using 
microtechnology and hard substrates such as silicon, glass and metallic thin films do not have 
moving parts such as pumps to release the drug [66, 67]. The drug, which is stored in 
multiple reservoirs in liquid, gel or solid form, can be discharged by applying a potential 
difference between an anode membrane covering a reservoir and a cathode. How to fill their 
reservoirs aseptically, how to seal the reservoirs hermetically, how to achieve 
biocompatibility, and how  to implant them through non-invasive surgery are some of the 
current difficulties associated with this class of implantable DDS [9, 16, 66, 67]. Another 
important problem is that a membrane grows around the device once it is implanted in the 
body. The membrane slows down the drug release and lessens the efficacy of these site-
specific drug delivery systems. If space is not a constraint, implantable micropump-based 
systems can beare more effective in satisfying the requirements of site-specific drug delivery. 
 
Encapsulated DDS can be in the form of micro/nano-sized drug containers made of polymers, 
gels, liposomes, micelles, proteins and antibodies, and relatively new and not clinically fully 
established peptides, viruses, cells, gold, iron oxide, carbon and silica nanoparticles, 
nanospheres, shells, sheets, diamonds, cubes, tubes, microcapsules and similar drug-
containing molecules [7, 17]. To accumulate them in tumours and at relevant sites for  
enhanced permeability and retention and to prevent their aggregation before achieving their 
desired effects, the size of these drug containers must be much less than 100 nm [7].  Smart 
soft materials such as electroactive polymers can be engineered as a drug container with a 
large amount of a drug to be released over a long period of time. They are encapsulated DDS 
implanted at a certain location inside or outside of the body so that they function to conceal 
the bad taste of a drug and improve drug stability and drug release characteristics. 
 
A telemetric technique has been proposed to govern an insulin pump for drug release [18].  
This technique is used to remotely control the time and rate of the drug. It is an implantable 
DDS like an electroactive polymer container releasing a drug over a long period of time, 
when it is remotely activated. The pump-based DDS can be placed externally and operated 
outside the body for drug delivery to transfer the drug in the liquid form from the drug 
reservoir to the blood vessel or tissue accurately and reliably, compared to conventional 
routes [19]. A typical drug delivery system based on a micropump is shown in Figure 2. Such 
devices usually need an on-board power source (e.g. a battery), which significantly affects the 
overall size of the device and where it can be implanted in and around the body [20]. On the 
other hand, an osmotic micropump [21] does not require energy and this means that a drug 
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delivery system based on an osmotic pump is much smaller and simpler than the actively 
operated mechanical displacement micropumps and electro and magneto-kinetic micropumps 
[22]. Their main disadvantages are that their operation is temperature dependent, and this can 
be problematic if the DDS is implanted externally, it does not allow refilling or multiple uses, 
and its release rate is constant and cannot be modified once it is set for use. 
 
Micro-electromechanical systems (MEMS) technology is used to establish implanted drug 
delivery devices which are assembled or implanted at an appropriate place in and around the 
body for  controlled drug release [66, 67]. The drug sealed with a thin film is released at the  
desired time and rate by rupturing the thin film using electrochemical and electro-thermal 
means [16, 18, 23-26].  
 
Figure 2: Elements of an implanted DDS based on a micropump concept. 
 
Figure 3: A practical drug release concept based on magnetic actuation, adapted from  [24]. 
 
 
Magnetic actuation has been proposed to minimize the overall size of the micropumps, which 
are activated by applying a magnetic field to a flexible magnetic reservoir containing a drug. 
The operation principle of such a magnetic drug delivery system is illustrated in Figure 3 [23, 
24]. This basic drug release concept is suitable for the robotic capsules [14, 15, 29, 30] for 
drug delivery in the gastrointestinal (GI) tract. The duration and magnitude of the magnetic 
field flux density determine the rate and amount of drug to be released. For example, a 
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compact magnetic drug release concept has been proposed to release a drug near the surface 
of the sclera (white part of the eye) to treat proliferative retinopathy in the eye [24]. It is 
implanted in the space surrounding the eye, towards the back of the eye. This is proposed as 
an alternative to a manually operated drug release system to treat chronic ocular diseases 
[27]. 
 
In addition to the external and implantable drug release systems based on the micropump 
concept, bioadhesives, polymer implants, transdermal patches, microencapsulation, 
microchip drug reservoirs, immuno-isolating capsules and diffusion chambers are other 
examples of implantable drug release/delivery systems [28]. Powering the implantable active 
DDS such as micropumps and associated wiring are two main challenges which must  be 
overcome before they can be used in vivo and subsequently in clinical applications. Wireless 
power transfer [72] is one option to consider though it is not easy because extra hardware 
must be brought in for energy generation and usage at the site.  
 
3. Soft Robotics for Drug Delivery 
Although there is no agreed definition of  the term ‘robotics’, we define robotics as the 
science and engineering of robots which are reprogrammable, multi-functional, multi-purpose 
and versatile systems and devices intelligently linking sensing to action. This definition can 
be extended to soft robotics as the science and engineering of the robots primarily made of 
soft materials, components and monolithic active structures so that they can safely interact 
with the natural world better than their predecessors (i.e. robots made of hard components). 
A robotic drug delivery system must have a minimum size as large as a vitamin pill, like a 
typical endoscopic capsule [15, 29, 30] (if it is operating within the digestive tract, which is 
the largest opening within the human body), a minimum drug release time (<1 second), a 
large enough volume of the drug reservoir (at least 30% its overall volume, storing not less 
than 0.3 mL of a drug), a high drug release rate and multiple doses. As it operates within the 
body, it is essential to have a soft robotic device in order to ensure that it does not apply 
excessive pressure on the tissues or organs and that it makes a soft-on-soft contact with an 
adaptable mechanical compliance matching with the tissues or organs along its path. 
 
A soft robotic system for drug delivery must meet the following requirements: 
 It must be biocompatible (biodegradable with no toxicity or harmful by-products, or 
not generating any harmful by-products if not biodegradable). 
 It must be mechanically and chemically strong against loads or pressure and harmful 
body fluids. 
 It must have adaptable compliance and shape match with organs, tissues and the like. 
It must be programmable, reliable and have localized drug delivery (dose, rate, 
timing). 
 There must be no drug degradation in the reservoir during the delivery period. 
 It must be economically viable for the patient, preferably re-usable for  long-term 
operation. 
 It must have wireless actuation, anchoring, localisation and control. 
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 It must be small enough to be operated within the body. 
 It must be simple to fabricate, sterilise, implement and remove.  
 It must be robust against accidental delivery. 
 It must meet  Food and Drug Administration (FDA) and European Medicine 
Evaluation Agency (EMEA) and similar agencies’ approval requirements. 
 
Current research issues in soft robotic devices for site-specific drug delivery centre on 
developing actuation, localisation, anchoring and drug release concepts satisfying these 
requirements, (see the expert Commentary Section). 
 
A soft robotic system needs energy. For an in-body robotic system, it is extremely difficult to 
store enough energy to activate any possible actuator (e.g. an overly miniaturised electric 
motor) for a long time (typically less than 10 minutes). While on-board batteries can be used 
for very short operations, other means such as electromagnetic induction, ionic signals, 
organic energy harvesting need to be considered. 
 
Recently, a starfish-like biocompatible, biodegradable and soft microgripper responsive to  
temperature change and a magnetic field [31, 32] has been  proposed for medical applications 
including drug delivery within the human body. Swelling and photo-cross-linked soft 
hydrogel containing iron oxide particles were  blended with a non-swelling and stiff 
segmented polymer to establish the gripper which opened and closed upon heating and 
cooling above and below 36
o
C, respectively. Although this concept has been used for cell 
gripping and excision, it can also be used for drug release within the body, assuming that it 
will be loaded with a drug which can be released upon activation. This is a good example of  
synthesising new soft and biocompatible materials which can be used to establish functional 
actuation concepts with a low foot-print (no batteries, power source, wires, tethers etc), 
amenable to remote actuation upon change in a remotely generated field or stimuli such as 
magnetic field and heat. Progress in soft robotics for medical applications within the human 
body depends on  progress in soft, biocompatible, and printable materials amenable to remote 
stimuli such as a magnetic field or a heat field, not requiring any on-board energy source. 
 
3.1. Robotic Drug Delivery Systems 
It is now unlikely that an autonomous robotic system with an on-board energy source could 
be devised for operation or drug delivery within the body especially in the GI tract. One 
possible robotic approach would be  to employ a robotic magnetic navigation system in the 
form of a robot manipulator carrying the magnetic source which externally navigates the 
target device in the body. Another one is a commercial magnetic navigation system [33], 
which carries a magnetic source to steer cardiovascular interventional devices [33, 34, 35], or   
gastrointestinal (GI) devices such as endoscopic capsules within the body [36, 65]. The 
commercial magnetic navigation system equipped with a fluoroscopic detector provides x-ray 
images and feedback data to the surgeon to update the location of the medical device within 
the body for any medical purpose such as screening, diagnostic or therapeutic purposes. The 
target device within the body has magnetic features interacting with the external navigation 
system. One of the disadvantages of these systems is that the magnetic field flux density 
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applied on the target robotic device containing a magnetic element is a nonlinear function of 
the distance between the magnetic source and the target points. When such systems operate 
under a magnetic field gradient, they generate a magnetic force to pull or push the medical 
device within the body. In addition to the disadvantage associated with the distance between 
the magnetic source and the target point, another disadvantage associated with this is the 
problem of safety. How to limit the magnetic field gradient in order to prevent any damage to 
the contacting tissue and patient is a challenging problem. The magnetic field gradient must 
generate a stress (through the target device within the body) less than the maximum stress ( 
<5-6 kPa) the surrounding tissue can withstand [34]. It must be noted that magnetic gradients 
provided by the imaging coils of an magnetic resonance imaging (MRI) scanner generated 
body depth-independent navigation forces on drug-loaded nanorobotic agents [57, 71]—
thanks to the high magnetic flux densities (at least 1.5 Tesla) provided by the scanner. 
 
Devising a truly soft robotic system to operate within the human body for drug delivery is 
challenging. One  recent proposal is a soft capsule robot for  drug delivery in the stomach 
[37-39]. It is a magnetically actuated soft capsule robot with a diameter of 15 mm and a 
length of 40 mm consisting of a camera module, two heads with internal magnets, a drug 
chamber, and side links connected between the two heads. It is activated externally with a 
pulse type magnetic field in the range of 0.01–0.07 T and with a frequency in the range of 1.2 
– 2 Hz to bring the heads closer in order to squeeze the drug out of the chamber. When 
squeezed, its diameter increases to 20 mm and its length decreases to 30 mm; 10 mm of the 
original length being the stroke needed for drug delivery. With these dimensions, it is suitable 
for operation in the stomach but not beyond, for drug delivery only, not for other functions 
such as biopsy or  biosensing yet. Another problem is that it does not deliver the drug at the 
target, but at four separate areas around the target. 
 
A remote controlled capsule [40] has been proposed for site-specific drug delivery within the 
GI tract. It has a diameter of 10.4 mm and a length of 30 mm and consists of a shell, a piston, 
an embedded magnetic marker, a tele-control unit, a drug release mechanism, and a magnetic 
switch. An external 330 MHz radio frequency signal is used to activate the drug release 
mechanism which consists of a micro-thruster, a sliding protective shell and a piston. The 
ignited propellant pushes the piston forward with enough force to discharge the full amount 
(0.6 mL) of the drug from  the drug reservoir. Although the size of the capsule may be 
acceptable, the problems  associated with this device are its small drug reservoir, the 
impossibility of multiple dose drug delivery and safety concerns due to using propellants and 
a thruster. Not having a dedicated anchoring mechanism when the thruster is ignited is a 
serious problem with this capsule. 
 
Woods and Constandinou [41] proposed a robotic capsule equipped with an anchoring 
mechanism and a drug release mechanism for site-specific drug delivery within the GI tract. 
It has a size of 32 mm in length and 11 mm in diameter, and contains micromotors to drive 
the anchoring and release mechanisms which occupy 60 % of the capsule volume. It was 
designed to deliver 1 ml of drug. No in vivo or in vitro drug delivery results have been 
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presented, however, in order to demonstrate whether this capsule is up to its task (i.e. drug 
delivery) specifications. 
 
The InteliSite® Capsule (Innovative Devices, Raleigh, US), which is an FDA approved 
cylindrical capsule with the dimensions of 10 mm in diameter, 35 mm in length with a drug 
reservoir of 0.8 ml, is radio frequency activated to deliver a drug within the GI tract. Gamma 
scintigraphy is used to localise the capsule within the GI tract and then the drug is remotely 
released. One important problem associated with this device is that there is no anchoring 
mechanism to ensure that the capsule does not move during the release period [123, 42, 43], 
and this is an essential feature of a robotic DDS. Other technical problems are drug leakage, 
the heat generating shape memory alloy actuators are used to activate the capsule, and 
activation times are greater than 2 minutes. The Enterion capsule (Phaeton Research 
Pharmaceutical Profiles) which has the dimensions of 9 mm in diameter, 32 mm in length 
with a drug reservoir of 1 ml of powder or liquid drug, was  developed to overcome some of 
the disadvantages of the Intelisite capsule [43]. An external magnetic field is applied to the 
capsule to increase the temperature of a heater element in the capsule in order to trigger the 
opening of the capsule and release the drug.  Compared to the Intelisite capsule, the release 
time is much quicker and it can deliver a wide range of drugs, however, in addition to its 
complex release mechanism, it does not have an anchoring mechanism to ensure that capsule 
is stopped at the delivery site during the release period. A new capsule or container-based 
DDS would need to have two essential features: (i) an anchoring mechanism to ensure that 
the device is stationed at the site of delivery and, (ii) a drug release mechanism to regulate the 
drug dose, release rate, and number of doses to be released. In general, there needs to be four 
modules in a soft robotic DDS:  actuation, localisation, anchoring and drug release. The 
release mechanism or technique used in the implantable DDS can be incorporated in the soft 
robotic DDS to expedite the progress in the robotic site-specific DDS. 
 
We have recently proposed a new magneto-mechanical robotic drug delivery system to be 
incorporated into the next generation wireless capsule endoscope (WCE), as illustrated in 
Figure 4 [44, 45]. It is based on a miniaturized slider-crank mechanism articulated with an 
externally induced magnetic torque. This system consists of three main components: the 
external magnetic system made of permanent magnets or an electromagnetic system (A) that 
surrounds the patient, the drug release module (B) embedded in the robotic capsule (C) and 
three complementary modules (D) integrated in the robotic capsule. The components of the 
drug release module are: an internal permanent magnet (IPM), a slider crank mechanism that 
is connected to the IPM, a drug reservoir to store the drug to be released and an orifice 
through which the drug is expelled as per the stroke of the slider-crank mechanism. We are in 
the process of testing this drug delivery system in a model of the GI tract. 
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Figure 4. The main components of  a drug delivery system for WCE. A: ring-shaped external magnetic system, 
B: drug release module, C: the robotic capsule, D: complementary modules within the capsule (anchoring 
mechanism, active locomotion system and localization and orientation detection module), E: patient bed, F: 
surgeon, G: joystick, H: Human Capsule Interface. 
 
3.2. Swarm-based DDS: Bacterial microsystems and microrobots 
In proportion to efforts to establish self-powered microrobots [46, 47], the propulsion 
mechanism of  microorganisms such as flagellar bacteria has been used as a model to design 
biomimetic microrobots to be operated  within narrow spaces inside the human body. Most of 
the established systems have been built as a macrorobot to validate the bio-inspired robotic 
concept. Another popular microrobotic model is flagellated magnetotactic bacteria (MTB) 
which are proposed as microcarriers for drug delivery within the circulatory system of human 
body where the hydrodynamics are described by a low Reynolds number. Both of these 
biologically inspired microrobotic concepts are magnetically actuated remotely. The latter, 
bacterial microrobot MTB, requires less power to operate. Of these bacteria, the rounded cell 
of the MC-1 magnetotactic bacterium with a diameter of 1-2 µm which has a large enough 
surface to hold a therapeutic agent (e.g. anti-cancer drug) had been proposed in order to move  
through the tiniest passages in humans to deliver the drug to specific points such as tumors 
[48, 49]. This is a computer-controlled therapeutic microrobot, which can move with and 
against blood flow with an accurate directional control, for example, using MRI-based 
actuation to magnetically guide these bacterial microrobots to a target [46, 71]. Detailed 
reviews of  microrobots and their applications are provided in [46, 47, 71]. 
 
Sperm-inspired microrobots that consist of a magnetic head and soft body have been  
developed for drug delivery applications [50]. An oscillating magnetic field as small as 5 mT  
is applied to the head to generate the  torque needed to oscillate the soft body and hence steer 
a supposedly drug loaded sperm-like microrobot to the drug delivery site. The potential 
medical uses include in vitro fertilization (IVF), cell sorting and opening clogged arteries. 
Formatted: Font color: Auto




A corkscrew structure made of plants is coated with titanium and magnetic nickel in order to 
build a microswimmer which is propelled via a rotational magnetic field in a wet 
environment [51]. This biodegradable microswimmer and other similar microswimmers [52] 
can be moved forward or backward and side-to-side in order to direct it to a desired location 
for drug delivery or to dig into blood clots in order to open obstructions in arteries and the 
like. Almost all microswimmers rely on a rotational or an oscillating body articulated through 
a magnetic field. Helical or oscillating magnetic structures can be fabricated using 3D 
fabrication techniques. These  structures can be loaded with drug, chemical, biological 
sensing molecules and the like. 
 
3.2.1. Magnetic Drug Carriers for Swarm-based DDS 
Intravenously administered drugs affect the whole body and can cause undesired side-effects 
as the drug diffuses not only into the target tumor/cells/organ, but also into  healthy ones. 
This means that site-specific drug delivery is essential in order to minimize any side effects. 
To this aim, many externally regulated stimuli-responsive drug delivery systems such as 
photo-responsive, magnetic field responsive, ultrasound-responsive, thermo-responsive and 
ultrasound-responsive systems have been proposed. Of these, the magnetic field responsive 
drug delivery systems are the most well studied and effective systems  and they have a high 
potential for use in  clinical applications as they guide a swarm of drug containers to the 
desired site using an external magnetic field. Magnetic drug carriers containing, for example, 
an anti-cancer agent such as doxorubicin, are guided to cancerous tumors within the body, 
and the drug is released using various mechanisms [53, 65]. A biocompatible magnetic 
nano/microparticle carrier loaded with a drug which is prepared as a biocompatible ferrofluid 
is dispensed into the circulatory system of a patient. An external magnetic field (~ 0.2 T) with 
a high enough gradient (~0.08-0.1 T/m) is applied to the target point in order to concentrate 
and keep the  desired dose of the carriers there. Using release mechanisms such as an 
enzymatic activity or a change in pH, osmosis, temperature, among others, the drug is 
released at the target point in vivo in order to obtain the maximum possible efficacy with little 
or no  side effects [53]. Hydrodynamics parameters  such as blood flow rate, drug 
concentration, infusion route and circulation time  and physiological parameters such as the 
distance from the magnetic field to the target site, reversibility and strength of the 
drug/carrier binding, and volume of the targeted tissue or tumor affect the success of such a 
typical site-specific drug delivery system based on magnetic drug carriers [53]. 
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Figure 5: A typical magnetic drug carrier with a ferrite core encapsulated with a biocompatible polymer shell in order 
to attach various drug formulations [53]. 
 
As shown in Figure 5, magnetic nano/microparticle carriers can be in the form of a 
ferromagnetic sphere (e.g., Fe3O4, or maghemite, γ-Fe2O3, cobalt, iron, nickel and similar). 
They are coated with a biocompatible polymer such as polyvinyl acetate (PVA) or dextran, or 
inorganic materials such as silica or a noble metal such as gold to protect them from the 
surrounding environment and attach them to functional groups such as carboxyl groups, 
biotin, avidin, carbodi-imide and other molecules holding the drugs or target antibodies [53]. 
 
Swarm based DDS are also known as magnetically targeted DDS. A swarm of magnetic 
microspheres is targeted to relevant sites or cells under an externally applied magnetic field, 
as demonstrated in Figure 6. Organic sheaths (as shown in Figure 5) are used to encapsulate 
the magnetic core so that a drug can be attached to microspheres and prevent the aggregation 
of the magnetic microspheres.  Magnetic navigation system is used to guide a swarm of the 
microspheres to the relevant sites [48, 49]. For example, the Stereotaxis robotic navigation 
system [33, 54] which is an FDA approved system can be used to navigate a swarm of micro-
particles to the desired site within the body, especially in the cardiovascular system. It 
generates a controlled magnetic field via two large coaxial permanent magnets assembled on 
automatically operated arms. It guides a magnetic catheter through the arterial system. Much 
research has been done into magnetic drug delivery systems [53, 55, 59, 61, 67], but for the 
sake of brevity, we are not including them.  
 
Formatted: Font color: Auto
Formatted: Centered
Formatted: Font color: Auto




Figure 6: Illustration of how magnetic drug carriers (MDC) in the circulatory system can be attracted to a 
relevant site using an external magnetic field, adapted from [56]. 
 
There are some research problems associated with  site-specific drug delivery based on 
magnetic drug carriers [48, 49, 53, 57-61]:  (i) occlusion of a blood vessel due to the  high 
concentration of the carriers just before  release, (ii) the distance from the magnetic field 
source to the target point--there is a non-linear relationship between the magnetic field and 
distance to the target point, (iii) once the drug is released, the blood flow reduces its efficacy, 
no retention of the drug under the magnetic field, and (iv) toxicity due to the magnetic core of 
the drug carrier. While the first two problems  can be solved using practical measures, the last 
two must be solved in order to pave the way for using this promising site-specific drug 
delivery technique in  clinical applications. 
 
Expert Commentary 
Compared to the swarm-based robotic DDS, the container-based robotic DDS are 
autonomous robotic systems, which carry a drug to various relevant locations within the body 
in order to release it as required multiple times. With this in mind, an actively operated 
capsule endoscopy for operation within the GI tract is a very good example of  the container-
based robotic DDS. A comprehensive review of  the diagnostic and therapeutic capabilities of 
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the actively navigated capsule endoscopy has recently been published [63]. Interested readers 
are encouraged to read that review paper to complement what is presented in this paper. 
Some critical research issues which need to be addressed for soft robotic systems for site-
specific drug delivery include:  
 
1. The progress in soft robotics strongly depends on the progress in materials science 
and technology. There is a need to establish materials the actuation and sensing 
properties of which can be programmed or varied using remotely applied fields such 
as a magnetic field or temperature change so they can be fabricated using additive 
manufacturing technologies to establish low footprint soft robotic systems. In general, 
there is an ongoing need for smart materials amenable to additive manufacturing and 
responsive to various stimuli such as electric, stress/pressure, light, heat, magnetic 
field, water/moisture, pH and the like, which change their various properties in a 
reproducible and predictable manner so that they can be used to establish actuators 
and sensors with a small footprint, meeting a strict space requirement for soft robotic 
devices for medical applications. 
 
2. As a soft robotic device needs to be actively navigated and there is a very limited 
space on board to store enough energy (i.e. battery), magnetic actuation appears to be 
the most viable  techniqueviable technique to use. To this end, a user- friendly hybrid 
magnetic system consisting of a permanent magnetic system and an electro-magnetic 
system is needed to navigate and anchor a soft robotic device and then release the 
drug in the chamber of the device. If a robotic DDS needs an on-board power source, 
the energy density of the current batteries will likely be insufficient, for example, for 
device propulsion, anchoring and drug release. For drug release only, the disk 
batteries in the current endoscopic capsules (3V, 55mAh ≅ 20 mW) will be sufficient 
as they last 8-9 hours for powering a number of LEDs, taking images and sending 
them wirelessly to an external data recorder. A detailed review of  endoscopic 
capsules is presented elsewhere [12, 13, 62, 63, 68]. 
 
3. We need to follow an integrated or mechatronic design approach when establishing a 
soft robotic system for drug delivery. To this aim, we propose to follow a top-down 
approach:  (i) understand the task or application requirements (e.g., site-specific drug 
delivery), (ii) develop design concepts for actuation, sensing, motion transmission, 
energy conversion and creation at the system level and component level, (iii) 
assuming that the actuators and sensors cannot be sourced from existing ones, 
determine material properties, and synthesise  materials which can easily be processed 
and 3D printable, to establish a monolithic device compactly hiding actuation, 
sensing, mechanical mechanism and control topology in its monolithic topology, and 
(iv) model, analyse, design optimise the device in the light of operation and 
fabrication constraints, and fabricate its prototype and finally test it under near-real 




4. Soft actuation with an energy or power source is the primary barrier to the 
construction of soft robotic systems. Flexible and compliant power sources 
incorporated into the monolithic topology containing the actuation system or 
externally induced into the topology are needed for soft robotic devices operating 
within the body. 
 
5. Most of the current drug delivery systems, especially the implanted ones, are the drug 
release systems. It will be a pragmatic approach to incorporate these drug release 
mechanisms, especially the microchip-based and MEMS based release systems into 
the new robotic DDS. 
 
6. There is a need for a low cost, low footprint localisation system (position and 
orientation relative to a reference coordinate frame) for robotic devices operating 
within the body. The recent innovative localisation method we proposed and the 
results we have presented to demonstrate its efficacy are the most accurate in the 
literature so far. The method, however, which is based on multiple (x3) positron 
emission markers requires a low cost gamma ray detection system [13-15], which is 
not currently available on the market as a stand-alone system. Therefore, this still 
remains as a challenging problem for in-body robotic systems including robotic DDS. 
 
7. For anchoring, there is a need for an anchoring system based on soft-on-soft contact, 
rather than those, like most of the systems in the literature, which are based on the 
hard-on-soft contact, thus  creating a safety concern. Recently, we have reported [64] 
on the fabrication of soft magnetic cilia and their assembly on the external surface of 
a typical capsule endoscope. An appropriately shaped magnetic field can be applied to 
the cilia to anchor the robotic capsule at the  desired location and then the drug is 
released using a drug release mechanism. Once the drug delivery and release is 
completed at a specified location, the magnetic field can be turned off in order to 
allow the capsule to travel along its path under  natural peristalsis.  In order to do this, 
this system requires only a  minimum modification to the existing capsule 
endoscopes. Once the magnetic field is turned off, the cilia can return to their 
collapsed neutral positions and do not create  any obstacle and/or hazard to the 
surrounding tissue. 
We expect this review to stimulate more interaction between many disciplines including 
engineering, medicine, materials science, chemistry, physics and biology in order to facilitate 
collaboration  on the establishment of functional soft robotic systems for medical 
applications.  This (i.e. functional soft robotic systems) has the potential to revolutionise 
medical diagnosis, procedures and treatment and subsequently provide unprecedented 
benefits to society. This collaboration will bring the necessary momentum and synergy to 
shorten the path from  laboratory-based research to clinical applications or devices which will 
be able to be approved by regulatory agencies such as the FDA and the EMEA. 
 
Five-year view 
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A typical robotic system consists of actuation, sensing, mechanical mechanism, control and 
communication interface elements. Such robotic systems are able to undertake intricate tasks 
requiring sophisticated positioning and force sensing abilities. Their control system is 
advanced enough to make contact with hard environments smoothly. On the other hand, soft 
robotic systems are made of (i) structural materials, making the skeleton of the robotic body, 
in the form of hard plastic or light metal alloys, which can tolerate some strain or deformation 
when under excessive load or stress, and (ii) soft smart materials which can be compactly 
hidden in and around the skeleton and overall topology of a soft robotic system to provide 
actuation, sensing, mechanical motion conversion and a control interface in order to facilitate 
a smooth human-machine interface. Softness and compliance matching are the important 
features of a soft robotic system, which need to be able to tolerate an unexpected contact with 
no damage to its environment. The concepts of embedded intelligence and morphological 
computation [1, 2]  can be employed for the design of a soft robotic DDS so that it will have  
simple and compact propulsion, localization, anchoring and release mechanisms. Both 
concepts mean outsourcing some intelligence and computation in the morphology of the soft 
robot made of smart and structural materials. This means that we can expect  significant 
progress in functional materials or what we call ‘soft robotic materials’ over  the next five  
years. These materials are expected to be amenable to additive manufacturing so  that the 
resulting multi-dimensional body can be programmed or allocated for actuation, sensing, 
control and communication interface and provide a  mechanical structure or mechanism, all 
in a single monolithic body. Modelling, analyzing and subsequently designing such a soft 
robotic device the behavior of which is heavily affected by the properties of the materials it is 
made of will be challenging research areas over  the next 5 years. 
 
Any autonomous drug delivery system must have propulsion, localization, and anchoring and 
release functions. There has been significant focus on their propulsion and drug release 
functions (which can be borrowed from the implantable DDS) as articulated in this paper and 
in recent reviews [12, 63]. We, therefore, believe that the primary focus over the next five 
years will be on the establishment of localizations and anchoring mechanisms. The anchoring 
mechanism needs to be compact and soft, and must not require  too much power to activate. 
We expect  significant progress in soft magnetic polymers fabricated as cilia, like actively 
controlled bristles, in the next 5 years to temporarily ground a robotic device (i.e. to anchor) 
to the drug delivery site. Most of the localization systems proposed for the container-based 
robotic drug delivery devices typified by an actively navigated capsule endoscope or robotic 
capsule are overly complex, requiring significant hardware and processing time to localize a 
device within the body, usually with  limited accuracy. By localization, we mean to 
determine the position and orientation of the device relative to a reference coordinate frame. 
Some localization systems are based on magnetic sensing [13, 15]. Knowing that magnetic 
actuation is promising or currently the only practical one, there will be interference between 
magnetic actuation and sensing (i.e. localization). We expect to see significant progress 
towards establishing a localization system which is low cost, accurate, minimally invasive, 
and able to work with actuation, anchoring and drug release mechanisms, neither being 
affected by them nor affecting them. A system approach based on considering all of these 
functions simultaneously needs to be followed in order to establish a functional robotic drug 
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delivery system which can meet various operation, delivery and regulation requirements. 
Within five  years, it will be possible to establish a magnetically controlled, autonomous soft 
robotic device for medical applications within the GI tract. 
 
The progress in additive manufacturing has been significant over  the last ten years.  It will 
further advance in the synthesis of processable and printable soft materials. The mechanical, 
electrical, and chemical properties of these materials can be tailored to meet the application 
requirements. The materials can be polymeric and metallic. A drop in the cost of 3D printers 
which can accept a range of soft and hard polymeric materials and metallic materials is 
expected.  
 
Magnetism appears to be the most suitable concept to remotely propel a robotic device, 
anchor it, release and do the site-specific drug delivery. Therefore, there is a need to develop 
a hybrid magnetic system consisting of a permanent magnetic system and a programmable or 
computer controlled electromagnetic system. Magnetic resonance imaging (MRI) systems 
[48, 49] have  been re-engineered for the real-time control and navigation of untethered 
magnetic carriers, nanorobots, and/or magnetotactic bacteria (MTB) loaded with sensory or 
therapeutic agents in the blood vessels. This is an expensive alternative to consider unless the 
drug delivery needs to be done in a hospital environment. Therefore, there is a pressing need 
for a low cost, user-friendly, and compact magnetic actuation and navigation system for the 
propulsion, anchoring and drug release of a container-based robotic DDS. Such a magnetic 
system will also be needed for swarm-based DDS, as illustrated in Figure 6.  
 
Much research into magnetic nanoparticles or drug carriers has been done. New magnetic 
nanoparticles for drug delivery, contrast agents for MRI, magnetic hyperthermia treatment 
etc. are being synthesised every day. We believe the progress will be in making 
biodegradable magnetic carriers, which do not create toxicity once their function is 
completed in the body/tissue/organ, and synthesising new magnetic carriers with a higher 
magnetic moment such that they require a smaller magnetic field to guide a swarm of them 
through the blood stream. 
 
Along with significant research progress in nanotechnology, microtechnology, smart 
materials, and intelligent mechatronic systems in the last decade, the field of site-specific 
DDS has been growing continuously to benefit from this progress in order to provide 
significant health benefits to society. We believe it is  time to consider a simple and effective 
site-specific drug delivery application to demonstrate this progress. As far as the robotic or 
autonomous DDS are concerned, the field of soft robotics and its sub-fields of micro soft 
robotics or milli soft robotics are still in their infancy. We expect an exponential growth in 
them over  the next five  years, which will lead to functional, soft and biocompatible robotic 
devices for medical applications such as screening, minimally invasive surgery, diagnosis and 
drug delivery within the human body. 
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Key issues 
 Site-specific drug delivery refers to physically carrying or transporting a drug to a 
specific location within the body, and discharging  or releasing  an appropriate 
(optimal) dose and rate of it when desired. 
 Site-specific DDS are classified into mechanical/physical, chemical and 
biological/molecular DDS.  
 Mechanical/physical DDS are  further divided into implantable and robotic / 
autonomous DDS. We focus on the latter, which is still in its infancy, and raises 
significant research questions which must be answered before it can meet the strict 
application, technical and regulation requirements. 
 Implantable DDS can be incorporated into the container-based robotic DDS as their 
drug release mechanism. 
 Magnetic actuation acts remotely, negating the need for an on-board power source for 
implantable micropump DDS. This significantly decreases the size of the 
micropumps. 
 If an implantable DDS requires on-board power, there is a need for high energy 
density batteries such as Li-ion batteries or the power must be induced wirelessly 
using a magnetic induction technique, which is complex to implement and operate. 
This applies to  container-based robotic DDS, too. 
 A container-based robotic DDS needs a minimum size as large as a vitamin pill, like a 
typical endoscopic capsule. 
 A container-based robotic DDS must have actuation, localisation, anchoring and drug 
release mechanisms intelligently hidden within its compact size. 
 The progress in soft robotic devices for medical applications depends on the progress 
in soft, biocompatible, and printable materials amenable to remote stimuli such as 
magnetic field or  heat field, not requiring any on-board energy source. 
 With current technology, it is not possible to have an autonomous robotic system with 
an on-board energy source, making magnetic actuation a strong candidate to articulate 
the robotic system. 
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 An external magnetic system remotely navigates a target robotic device in the body, 
assuming that the anchoring and drug release mechanisms can be activated using an 
on-board power source, which will intermittently be used during the anchoring and 
drug release times only. 
 Swarm-based DDS in the form of bacterial microsystems are inspired from the 
flagellar bacteria, usually requiring a remotely applied magnetic field. 
 Swarm-based DDS responsive to a magnetic field are the most effective ones to guide 
the device to a desired site. 
 The research challenges for the container-based robotic DDS are the same as the 
actively operated endoscopic capsules. 
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